Merrimack Pharmaceuticals Inc. Secures $60,000,000 Series F Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1d2cc4d3-a794-49eb-b5ae-ff57592ec0b9&Preview=1 -
Date
6/10/2008 -
Company Name
Merrimack Pharmaceuticals Inc. -
Mailing Address
One Kendall Square, Building 700, 2nd Fl Cambridge, MA 02139 -
Company Description
Merrimack Pharmaceuticals, Inc. is a privately held biotechnology company based in Cambridge, Massachusetts. We are dedicated to the discovery and development of innovative therapies for the treatment of autoimmune disease and cancer. -
Website
http://www.merrimackpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$60,000,000 -
Transaction Round
Series F -
Proceeds Purposes
Proceeds from the financing will be used to advance Merrimack’s proprietary pipeline of biologic therapiestargeting autoimmune disease and cancer. -
M&A Terms
-
Venture Investor
Credit Suisse -
Venture Investor
Crocker Capital -
Venture Investor
Undisclosed
